FOI 7337 - biologic and biosimilar products within Rheumatology

Date: 25 April 2022 to 25 April 2025

It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: 

  • Abatacept [Orencia] 
  • Adalimumab [Humira] 
  • Adalimumab Biosimilars 
  • Apremilast [Otezla] 
  • Baricitinib [Olumiant] 
  • Certolizumab [Cimzia] 
  • Etanercept [Enbrel] 
  • Etanercept Biosimilars 
  • Filgotinib [Jyseleca]  
  • Golimumab [Simponi] 
  • Guselkumab [Tremfya] 
  • Infliximab [Remicade] 
  • Infliximab Biosimilars 
  • Ixekizumab [Taltz] 
  • Risankizumab [Skyrizi] 
  • Rituximab [MabThera] 
  • Rituximab Biosimilars 
  • Sarilumab [Kevzara] 
  • Secukinumab [Cosentyx] 
  • Tocilizumab [Ro Actemra] 
  • Tofacitinib [Xeljanz] 
  • Upadacitinib [Rinvoq] 
  • Ustekinumab [Stelara] 
  • Request ID:
    7337
  • Category:
    Clinical - Drugs
  • Response:

    May 2022

    Thank you for your recent request under the Freedom of Information Act 2000.

    The information you have requested is as follows:

     

    It would be really helpful if you could provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs: 

    • Abatacept [Orencia] 
    • Adalimumab [Humira] 
    • Adalimumab Biosimilars 
    • Apremilast [Otezla] 
    • Baricitinib [Olumiant] 
    • Certolizumab [Cimzia] 
    • Etanercept [Enbrel] 
    • Etanercept Biosimilars 
    • Filgotinib [Jyseleca]  
    • Golimumab [Simponi] 
    • Guselkumab [Tremfya] 
    • Infliximab [Remicade] 
    • Infliximab Biosimilars 
    • Ixekizumab [Taltz] 
    • Risankizumab [Skyrizi] 
    • Rituximab [MabThera] 
    • Rituximab Biosimilars 
    • Sarilumab [Kevzara] 
    • Secukinumab [Cosentyx] 
    • Tocilizumab [Ro Actemra] 
    • Tofacitinib [Xeljanz] 
    • Upadacitinib [Rinvoq] 
    • Ustekinumab [Stelara] 

    Patient Count of Medication Issued in 01/02/2022 to 30/04/2022

    Speciality: Rheumatology

    Drug

    Number of Patients

    ABATACEPT

    <5

    ABATACEPT (ORENICA) - HOMECARE

    71

    ADALIMUMAB (AMGEVITA) - HOMECARE

    <5

    ADALIMUMAB (HUMIRA) - HOMECARE

    64

    ADALIMUMAB (IMRALDI) - HOMECARE

    288

    APREMILAST (OTEZLA) - HOMECARE

    12

    BARICITINIB (OLUMIANT) - HOMECARE

    36

    CERTOLIZUMAB (CIMZIA) - HOMECARE

    18

    ETANERCEPT (BENEPALI) - HOMECARE

    329

    ETANERCEPT (ENBREL) - HOMECARE

    30

    ETANERCEPT (ERELZI) - HOMECARE

    <5

    GOLIMUMAB (SIMPONI) - HOMECARE

    117

    INFLIXIMAB (INFLECTRA)

    <5

    INFLIXIMAB (REMICADE)

    9

    INFLIXIMAB (REMSIMA)

    13

    INFLIXIMAB (REMSIMA) - HOMECARE

    12

    RITUXIMAB (RIXATHON)

    <5

    RITUXIMAB (TRUXIMA)

    15

    SECUKINUMAB (COSENTYX) - HOMECARE

    54

    TOCILIZUMAB

    25

    TOCILIZUMAB (ROACTEMRA) - HOMECARE

    105

    TOFACITINIB(XELJANZ) - HOMECARE

    <5

    USTEKINUMAB (STELARA) - HOMECARE

    8

     

    *Please note if the drug has not been listed it has not been used